P2X7: a Receptor with a Split Personality That Raises New Hopes for Anti-cancer Therapy

Overview

Journal Purinergic Signal

Publisher Springer

Date 2021 Apr 5

PMID 33818742

Citations 2

Authors

Alba Clara Sarti

Valentina Vultaggio-Poma

Francesco Di Virgilio

Affiliations

Soon will be listed here.

Citing Articles

Agonists, Antagonists, and Modulators of P2X7 Receptors.

Muller C, Namasivayam V Methods Mol Biol. 2022; 2510:31-52.

PMID: 35776318 DOI: 10.1007/978-1-0716-2384-8_2.

P2X7 receptor involved in antitumor activity of atractylenolide I in human cervical cancer cells.

Han Y, Bai C, He X, Ren Q Purinergic Signal. 2022; 19(1):145-153.

PMID: 35235139 PMC: 9984620. DOI: 10.1007/s11302-022-09854-6.

References

Ferrari D, Wesselborg S, Bauer M, Schulze-Osthoff K . Extracellular ATP activates transcription factor NF-kappaB through the P2Z purinoreceptor by selectively targeting NF-kappaB p65. J Cell Biol. 1998; 139(7):1635-43. PMC: 2132650. DOI: 10.1083/jcb.139.7.1635. View

Salas-Benito D, Perez-Gracia J, Ponz-Sarvise M, Rodriguez-Ruiz M, Martinez-Forero I, Castanon E . Paradigms on Immunotherapy Combinations with Chemotherapy. Cancer Discov. 2021; 11(6):1353-1367. DOI: 10.1158/2159-8290.CD-20-1312. View

Gelin C, Bhattacharya A, Letavic M . P2X7 receptor antagonists for the treatment of systemic inflammatory disorders. Prog Med Chem. 2020; 59:63-99. DOI: 10.1016/bs.pmch.2019.11.002. View

Stokes L, Bidula S, Bibic L, Allum E . To Inhibit or Enhance? Is There a Benefit to Positive Allosteric Modulation of P2X Receptors?. Front Pharmacol. 2020; 11:627. PMC: 7235284. DOI: 10.3389/fphar.2020.00627. View

Di Virgilio F, Giuliani A, Vultaggio-Poma V, Falzoni S, Sarti A . Non-nucleotide Agonists Triggering P2X7 Receptor Activation and Pore Formation. Front Pharmacol. 2018; 9:39. PMC: 5799242. DOI: 10.3389/fphar.2018.00039. View

Adinolfi E, Raffaghello L, Giuliani A, Cavazzini L, Capece M, Chiozzi P . Expression of P2X7 receptor increases in vivo tumor growth. Cancer Res. 2012; 72(12):2957-69. DOI: 10.1158/0008-5472.CAN-11-1947. View

Mimoto F, Tatsumi K, Shimizu S, Kadono S, Haraya K, Nagayasu M . Exploitation of Elevated Extracellular ATP to Specifically Direct Antibody to Tumor Microenvironment. Cell Rep. 2020; 33(12):108542. DOI: 10.1016/j.celrep.2020.108542. View

Kamata-Sakurai M, Narita Y, Hori Y, Nemoto T, Uchikawa R, Honda M . Antibody to CD137 Activated by Extracellular Adenosine Triphosphate Is Tumor Selective and Broadly Effective without Systemic Immune Activation. Cancer Discov. 2020; 11(1):158-175. DOI: 10.1158/2159-8290.CD-20-0328. View

Douguet L, Janho Dit Hreich S, Benzaquen J, Seguin L, Juhel T, Dezitter X . A small-molecule P2RX7 activator promotes anti-tumor immune responses and sensitizes lung tumor to immunotherapy. Nat Commun. 2021; 12(1):653. PMC: 7843983. DOI: 10.1038/s41467-021-20912-2. View

10.

Baricordi O, Ferrari D, Melchiorri L, Chiozzi P, Hanau S, Chiari E . An ATP-activated channel is involved in mitogenic stimulation of human T lymphocytes. Blood. 1996; 87(2):682-90. View

11.

Di Virgilio F, Dal Ben D, Sarti A, Giuliani A, Falzoni S . The P2X7 Receptor in Infection and Inflammation. Immunity. 2017; 47(1):15-31. DOI: 10.1016/j.immuni.2017.06.020. View

12.

Lara R, Adinolfi E, Harwood C, Philpott M, Barden J, Di Virgilio F . P2X7 in Cancer: From Molecular Mechanisms to Therapeutics. Front Pharmacol. 2020; 11:793. PMC: 7287489. DOI: 10.3389/fphar.2020.00793. View

13.

De Marchi E, Orioli E, Pegoraro A, Sangaletti S, Portararo P, Curti A . The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment. Oncogene. 2019; 38(19):3636-3650. PMC: 6756114. DOI: 10.1038/s41388-019-0684-y. View

14.

Surprenant A, Rassendren F, Kawashima E, North R, Buell G . The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science. 1996; 272(5262):735-8. DOI: 10.1126/science.272.5262.735. View

15.

Di Virgilio F, Schmalzing G, Markwardt F . The Elusive P2X7 Macropore. Trends Cell Biol. 2018; 28(5):392-404. DOI: 10.1016/j.tcb.2018.01.005. View

16.

Adinolfi E, Capece M, Franceschini A, Falzoni S, Giuliani A, Rotondo A . Accelerated tumor progression in mice lacking the ATP receptor P2X7. Cancer Res. 2014; 75(4):635-44. DOI: 10.1158/0008-5472.CAN-14-1259. View

17.

Solini A, Chiozzi P, Morelli A, Fellin R, Di Virgilio F . Human primary fibroblasts in vitro express a purinergic P2X7 receptor coupled to ion fluxes, microvesicle formation and IL-6 release. J Cell Sci. 1999; 112 ( Pt 3):297-305. DOI: 10.1242/jcs.112.3.297. View

18.

Di Virgilio F, Bronte V, Collavo D, Zanovello P . Responses of mouse lymphocytes to extracellular adenosine 5'-triphosphate (ATP). Lymphocytes with cytotoxic activity are resistant to the permeabilizing effects of ATP. J Immunol. 1989; 143(6):1955-60. View

19.

Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, Di Virgilio F . Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS One. 2008; 3(7):e2599. PMC: 2440522. DOI: 10.1371/journal.pone.0002599. View

20.

Di Virgilio F . P2X7 is a cytotoxic receptor….maybe not: implications for cancer. Purinergic Signal. 2020; 17(1):55-61. PMC: 7955003. DOI: 10.1007/s11302-020-09735-w. View